MDMB-FUBICA

MDMB-FUBICA

MDMB-FUBICA

Chemical compound


MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1]

Quick Facts Legal status, Identifiers ...

It was first detected by the EMCDDA in Sweden in February 2015.[2] It is often sold in e-liquid form for use in an electronic cigarette.[3]

Side effects

MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015.[4]

Legality

MDMB-FUBICA is banned in Sweden.[5]

See also


References

  1. Wagmann L, Stiller RG, Fischmann S, Westphal F, Meyer MR (October 2022). "Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases". Archives of Toxicology. 96 (10): 2755–2766. doi:10.1007/s00204-022-03332-z. PMC 9352624. PMID 35788413.
  2. "Hamarosan: 2015. Évi Európai Kábítószer - Jelentés" [Coming soon: 2015. Annual European Drugs - Report] (PDF). Hungarian National Focal Point (NFP). June 2015. Retrieved 23 July 2015.
  3. Peace MR, Krakowiak RI, Wolf CE, Poklis A, Poklis JL (February 2017). "Identification of MDMB-FUBINACA in commercially available e-liquid formulations sold for use in electronic cigarettes". Forensic Science International. 271: 92–97. doi:10.1016/j.forsciint.2016.12.031. PMC 5511053. PMID 28076838.
  4. "Очередная жертва спайса" [Another victim of spice]. Federal Drug Control Service of the Russian Federation. 17 March 2015. Archived from the original on 14 July 2015. Retrieved 24 July 2015.
  5. "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara" [23 new substances can be classified as narcotics or health hazards]. Folkhälsomyndigheten (The Public Health Authority). 1 June 2015. Retrieved 24 July 2015.

Share this article:

This article uses material from the Wikipedia article MDMB-FUBICA, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.